Trusted therapy
supported by Indian
and International Studies
US FDA approved for the
prevention of recurrent
spontaneous preterm birth
ACOG’s clinical guidance
recognizes as ‘Prediction and
Prevention’ of preterm birth
Dosage form: |
Depot Release Injection |
Therapeutic Class: |
Progestogen for progesterone deficiency during pregnancy |
Composition: |
17α-Hydroxyprogesterone Caproate – 250mg/ml |
Packing Monocarton: |
17α-Progestogen for progesterone deficiency during pregnancy |
Strengths available: |
500mg and 250mg |
Dosage form: |
Depot Release Injection |
Therapeutic Class: |
Progestogen for progesterone deficiency during pregnancy |
Composition: |
17α-Hydroxyprogesterone Caproate – 250mg/ml |
Packing Monocarton: |
17α-Progestogen for progesterone deficiency during pregnancy |
Strengths available: |
500mg and 250mg |